Endogenous subclinical hyperthyroidism, defined by normal circulating levels of free T4 and T3 and low levels of TSH, is a common clinical entity and is typically caused by the same conditions that account for the majority of cases of overt hyperthyroidism: Graves' disease, toxic multinodular goiter, and solitary autonomously functioning thyroid nodules. Subclinical hyperthyroidism has been associated with an increased risk of atrial fibrillation and mortality, decreased bone mineral density in postmenopausal women, and mild hyperthyroid symptoms. Treatment of subclinical hyperthyroidism remains controversial, given the lack of prospective randomized controlled trials showing clinical benefit with restoration of the euthyroid state. Nevertheless, it seems reasonable to treat older individuals whose serum TSH levels are less than 0.1 mU/liter and certain highrisk patients, even when the serum TSH is between 0.1 and the lower limit of the normal range. Copyright © 2007 by The Endocrine Society.
CITATION STYLE
Cooper, D. S. (2007). Approach to the patient: Approach to the patient with subclinical hyperthyroidism. Journal of Clinical Endocrinology and Metabolism, 92(1), 3–9. https://doi.org/10.1210/jc.2006-2472
Mendeley helps you to discover research relevant for your work.